In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2,5-dimethoxyphenylethyl)]-N′[2-(5-bromopyridyl)]-thiourea (HI-236), a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase

Arzneimittel-Forschung/Drug Research

Volumn 51, Issue 7, 2001, Pages 574-581

  Chen, C L ^a   Venkatachalam, T K ^a   Waurzyniak, B ^a   Chelstrom, L ^a   Uckun, F M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

Author keywords

CAS 233271 65 3; HI 236, in vivo toxicity, mouse, pharmacokinetics; HIV 1 reverse transcriptase, non nucleoside inhibitor; N 2 (2,5 dimethoxyphenylethyl) N 2 (5 bromopyridinyl) thiourea

Indexed keywords

ANTIVIRUS AGENT; HI 236; N [2 (2,5 DIMETHOXYPHENYLETHYL)] N' [2 (5 BROMOPYRIDYL)]THIOUREA; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; DRUG RESEARCH; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; LETHARGY; MOUSE; MULTIDRUG RESISTANCE; NEUROTOXICITY; NONHUMAN; TISSUE DISTRIBUTION; VIRUS INHIBITION;

EID: 0034913057     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300082     Document Type: Article

References (16)

1. Non-nucleoside inhibitors of HIV-1 reverse transcriptase
2. The role of non-nucleoside reverse transcriptase inhibitors (NNRIs) in the therapy of HIV-1 infection
3. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase
4. Rational design of N-[2-(2,5-dimethoxyphenylethyl)]-N′-[2-(5-bromopyridyl)-thiourea (HI-236) as a potent nonnucleoside inhibitor of drug-resistant human immunodeficiency virus
5. Structure-based design of N-[2-(1-piperidinylethyl)]-N′[2-(5-bromopyridyl)]-thiourea and N-[2-(1-piperazinylethyl)-N′-[2-(5-bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase
6. Evaluation of the pharmacokinetic features and tissue distribution of the potent nonnucleoside inhibitor of HIV-1 revese transcriptase, N-[2-(2-fluorophenethyl)]-N′[2-(5-bromopyridyl)]-thiourea (HI-240) with an analytical HPLC method
7. Pharmacokinetics and biological activity of the novel mast cell inhibitor, 4-(3prime;-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline in mice
8. Quantitative high-performance liquid chromatography based detection method for calphostine C, a naturally occurring perylenequinone with potent antileukemic activity
9. In vivo toxicity, pharmacokinetics, and anticancer activity of genistein conjugated to human epidermal growth factor
10. In vivo toxicity and pharmacokinetic features of B43(anti-CD19)-genistein immunoconjugate in non-human primates
11. Dimethyl sulfoxide: Its steroid solubility and endocrinologic and pharmacologic-toxicologic characteristics
12. A toxicological study of dimethyl sulfoxide
13. Physiological parameters in laboratory animals and humans
14. The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase
15. Tissue distribution and metabolic disposition of zidovudine in rats